This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the safety and effectiveness of the VitaSmart Liver Machine Perfusion System by comparing clinical outcomes in patients undergoing liver transplantation with ex-vivo liver preservation using static cold storage (SCS) followed by hypothermic oxygenated machine perfusion (HOPE) versus SCS only.
Patients on the UNOS waiting list for liver transplantation who have been consented, meet study eligibility criteria and are matched to a liver allograft from donation after brain death (DBD) or donation after circulatory death (DCD) that meet the extended risk eligibility criteria will be randomized 1:1 to SCS followed by HOPE (HOPE arm) or to SCS only (SCS arm). The objective of the study is to demonstrate the safety and effectiveness of the VitaSmart Liver Machine by comparing endpoints between the HOPE and SCS arms. Following transplantation, patients will be monitored daily (labs, adverse events, medications/procedures) while inpatient, and then additionally on Days 14 and 30 and Months 3, 6 and 12. The primary efficacy endpoint of early allograft dysfunction (EAD) rate will be assessed between HOPE and control using a non-inferiority design. An interim analysis is planned after approximately 70% of patients have been completed primary endpoint data collection to assess for early study completion based on non-inferiority or superiority.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
219
Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.
Donor liver retrieval and preservation using standard of care cold storage methods
Loma Linda University Medical Center
San Bernardino, California, United States
University of California San Francisco
San Francisco, California, United States
Proportion of patients with early allograft dysfunction (EAD)
Time frame: At Day 7 post-transplant
Model for early allograft function (MEAF) score
Based on definition by Olthoff et al, 2010 (doi: 10.1002/lt.22091)
Time frame: Within 3 days post-transplant
Proportion of patients with primary non-function (PNF)
Based on definition by Pareja et al, 2015 (doi: 10.1002/lt.23990)
Time frame: Within 7 days post-transplant
Length of hospital stay
Duration from initial ICU admission to hospital discharge order (measured in days)
Time frame: Up to study participation ends at 1-year follow-up
Length of intensive care unit stay
Duration from initial ICU admission to ICU discharge order (measured in days)
Time frame: Up to study participation ends at 1-year follow-up
Duration on dialysis
Duration from establishment of graft reperfusion until discontinuation of dialysis (measured in days)
Time frame: Up to study participation ends at 1-year follow-up
Donor liver utilization rate
Time frame: Up to study participation ends at 1-year follow-up
Patient survival rate
Time frame: 30 days, 6 months, 1 year post-transplant
Graft survival rate
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Stanford University Medical Center
Stanford, California, United States
Mayo Clinic
Jacksonville, Florida, United States
Cleveland Clinic
Weston, Florida, United States
Indiana University
Indianapolis, Indiana, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Lahey Hospital and Medical Center
Burlington, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
Washington University St. Louis
St Louis, Missouri, United States
...and 6 more locations
Time frame: 30 days, 6 months, 1 year post-transplant
Incidence of adverse events (AEs)
Time frame: 1 year post-transplant
Incidence of serious AEs (SAEs)
Time frame: 1 year post-transplant
Incidence of unanticipated adverse device effects (UADEs)
Time frame: 1 year post-transplant
Incidence of ischemic cholangiopathy
Time frame: 6 months, 1 year post-transplant
Incidence of biopsy-proven liver rejection
Time frame: 6 months, 1 year post-transplant